- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027738
a Single Intraarticular Injection of PRP for Early Knee OA
Efficacy of a Single Intraarticular Injection of Platelet-Rich Plasma for the Treatment of Early Knee Osteoarthritis
Study Overview
Detailed Description
Platelet-rich plasma (PRP) has been reported to be effective for the treatment of knee osteoarthritis (OA). This study aimed to investigate the efficacy of a single intraarticular injection of PRP for the treatment of early knee OA.
In a prospective trial with 6-month follow-up, patients with early knee OA were recruited and received a single intraarticular PRP injection. Several outcomes were measured.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 813
- Department of Physical Medicine and Rehabilitation, Veterans General Hospital,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 20-70 years
- symptomatic knee OA with pain for at least 6 months despite conservative treatment such as analgesics, NSAIDs and/or physical therapy
- average knee pain of at least 30 mm on a 100-mm visual analog (VAS) scale
- grade 1 or 2 knee OA according to the Kellgren-Lawrence grading system based on -radiographs taken within the previous 6 months
- Radiological evidence of bilateral knee OA was accepted if global pain VAS in the contralateral knee was less than 30 mm.
Exclusion Criteria:
- previous orthopedic surgery on the spine or lower limbs
- disabling OA of either hip or foot
- knee instability or marked valgus/varus deformity
- history of severe knee trauma; intraarticular injections into the knee in the past 6 months
- infections or skin diseases around the target knee
- women ascertained or suspected pregnancy or lactating
- presence of malignancy, hematological disease, collagen vascular diseases, or autoimmune diseases;
- therapy with anticoagulants or anti-aggregating agent
- serious medical conditions that would interfere with the assessments during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRP injection
The patients received a single 3-ml injection of PRP.
|
The patients received a single 3-ml injection of PRP.
Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes.
The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS pain
Time Frame: 6 months
|
The primary outcome was the change from baseline in the VAS pain score at 6 months.
The patient rated the average severity of knee pain on knee movement over the previous week on a 0-100 mm VAS (0=no pain to 100=worst possible pain)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time Frame: 6 months
|
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, Likert Scale) is a 24-item questionnaire with 3 subscales measuring pain, stiffness, and physical function [17].
The patient answers the questions and then receives a cumulative score in each of the 3 areas (pain, 0-20; stiffness, 0-8; physical function, 0-68).
Total score is 96 and higher scores indicate worse outcomes.
|
6 months
|
Lequesne index
Time Frame: 6 months
|
Lequesne index is used to assess severity of knee symptoms during the last week .It is validated and includes the measurement of pain (5 items), walking distance (2 items), and activities of daily living (4 items).
Maximal score is 24 and higher scores represent worse function.
|
6 months
|
Single-leg stance test (SLS)
Time Frame: 6 months
|
Single-leg stance test (SLS) is done by raising one foot up without touching it to the supported lower extremity with target knee and maintain balance for as long as possible.
Each participant performed 3 trials, and the best result of the 3 trials was recorded
|
6 months
|
Patients satisfaction
Time Frame: 6 months
|
Patients were asked to rate their treatment satisfaction compared to the preinjection condition, using a 100 mm VAS (0= completely dissatisfied, 100=completely satisfied)
|
6 months
|
safety assessment
Time Frame: during the study, for 6 months
|
The safety assessment was based on adverse events reported by the patients during the study and physical findings by the evaluator at each follow-up.
The occurrence of adverse events was recorded, including duration, action taken and outcome.
|
during the study, for 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shu Fen Sun, MD, Kaohsiung Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VGHKS106-131
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on PRP
-
Sun Yat-sen UniversityUnknownSevere Non-proliferative Diabetic RetinopathyChina
-
Ankara Universitesi TeknokentCompleted
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriapical Lesions
-
Cairo UniversityRecruiting
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingDry Age-related Macular DegenerationItaly
-
Yantai Yuhuangding HospitalRecruitingKnee OsteoarthritisChina
-
Yantai Yuhuangding HospitalTerminated
-
Anita Syla LokajEnrolling by invitation